In addition to its favorable involvement in gastric adenocarcinoma regarding disease-free survival, CX3CL1 has also been documented to boost the immune system’s anti-tumor activity against LIHC and improve the prognosis of patients with hepatocellular carcinoma (Hyakudomi et al., 2008; Huang and Geng, 2010; Ashour et al., 2020; Yang et al., 2022). Here, CX3CL1 is linked to neoplasm.